The approval of tirzepatide, the first dual incretin agonist, for the treatment of type 2 diabetes ushered in a “new era of metabolic medicine,” according

In type 2 diabetes, ARMMS-T2D is the largest and longest-running comparison of metabolic surgery versus medical and lifestyle intervention. In a symposium held on Monday,

This paper was presented on June 25 at the 83 American Diabetes Association ( ADA) Annual Scientific Session at San Diego by Drs Yong Soo

This paper was presented on June 25 at the 83 American Diabetes Association ( ADA) Annual Scientific Session at San Diego by Drs James Amamoo,

According to new research, positive discordance as measured by a glycation ratio of glucose management indicator and haemoglobin A1c (GMI/A1c) was associated with a risk

On June 26 2023, the American Diabetes Association® (ADA) presented Carmella Evans-Molina, MD, PhD, Eli Lilly Professor of Paediatric Diabetes, Indiana University (IU) School of

In the symposium Engineering and Site Consideration for Cell Therapy on Monday, June 25, panellists discussed cell therapy and the mission to develop new methods

Approximately fifty percent of patients with endstage renal disease in developed countries have diabetes, according to the National Institutes of Health (NIH), and the prevention

There is accumulating evidence regarding the cardiovascular benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists in patients with type

This paper was presented by Drs Jean Lu, Cheng Yi Yuan, Yee W. Kong, Emma Netzer, Huanping Wu, Thomas Seidl, David N. O’neal from Melbourne,